Medical treatment research by the gene cluster (EPR-1, dCK, and TP) which guides antineoplastic drug susceptibility reinforcement
Medical treatment research by the gene cluster (EPR-1, dCK, and TP) which guides antineoplastic drug susceptibility reinforcement
批准号:
13470262
负责人:
TANIGAWA Nobuhiko
金额:
$9.86万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2003
中文摘要
将潜在的Survivin反义基因EPR-1连接到含有金属硫蛋白启动子的载体pMTN2中。然后将pMTN2-EPR-1载体导入人结肠腺癌细胞HT29(Survivin表达阳性)。锌可诱导EPR-1高表达的HT29-AS33和HT29-AS49亚系细胞发生凋亡,并增加对顺铂和5-FU的体外敏感性。然后,结合今后的临床研究,构建了表达EPR-1的重组腺病毒载体(Ad.CMV-EPR-1),并对其在裸鼠HT29裸鼠移植瘤上的体内抗肿瘤作用进行了评价。当移植瘤直径大于或等于8 mm时,给荷瘤小鼠一次性注射Ad.CMV-EPR1和Ad.CMV-LacZ。前者肿瘤形成率为对照组的1/4。提示其作用机制可能与诱导HT29细胞凋亡有关。此外,顺铂或5-FU联合Ad.CMV-EPR-1的疗效得到提高,肿瘤体积…降低分别增加25%和16%(EUJ癌症出版社)。此外,我们先前的研究表明,携带dThdPase(TP)表达载体的细胞对5‘-DFUR和5-FU更敏感(BR J癌症75,1997)。因此,在本研究的同时,将1.5kb的TPcDNA转移到逆转录病毒载体pNV7的EcoRI位点,获得了转染腺癌细胞MC38-TP和MC38-Neo的细胞系。Western印迹和ELISA法分析表明,在MC38-TP中可检测到TP的表达,而在对照组中未检测到TP的表达,且两个亚克隆的生长速度相同。由于前者在体外对5-FU、5‘-DFUR和卡培他滨的敏感性显著增加,体内实验也通过皮下接种MC38-TP小鼠模型进行,证实了5’-DFUR和卡培他滨对MC38-TP的化疗效果增强(数据提交)。这种与化疗敏感性相关的基因研究可能有助于为目前的癌症化疗提供有效的改进。较少
英文摘要
EPR-1 cDNA, a potential survivin antisense, was ligated into a plasmid vector (pMTN2) with metallothionein promoter. Then HT29 human colon adenocarcinoma cells (with positive survivin expression) were transfected with the pMTN2-EPR-1 plasmid vector. Apoptosis was induced in HT29-AS33 and HT29-AS49 subolones with high EPR-1 expression in the presence of Zinc and furthermore sensitivity to Cis-DDP and 5-FU in vitro was increased. Then, on the basis of future clinical development, EPR-1 expressing adenovirus vector (ad.CMV-EPR-1) was made and the in vivo antitumor treatment was assessed on nude mouse HT29 xenografts. When the xenografts were 8mm or more, Ad.CMV-EPR1 and Ad.CMV-LacZ were injected to the tumor bearing mice once. In former group tumor formation was reduced to 1/4 comparing to the controls. This, suggested that the effect was due to HT29 cell line apoptosis induction. In addition, efficacy of CDDP or 5-FU combination with Ad.CMV-EPR-1 was enhanced, with reduction in tumor vol … More ume of 25% and 16% respectively (Eur J Cancer, in Press). Moreover, we have previously shown that transfected cells with plasmid vector expressing dThdPase(TP) cDNA were more sensitive to 5'-DFUR and 5-FU(Br J Cancer 75,1997). Therefore, at the time of this study, TPcDNA (1.5 kb) was transferred to EcoRI site of a retroviral vector, -pNV7 and transfected murine adenocarcinoma cell lines of MC38-TP and MC38-Neo were obtained. In Western blot and ELISA analysis the expression of TP was detected in MC38-TP, but not in the controls and the growth rate of both subclones was identical. As increased sensitivity to 5-FU,5'-DFUR and Capecitabine was significantly observed in vitro for the former group, in vivo experiment was also studied using subcutaneously inoculated MC38-TP mouse models which confirmed the enhancement of 5'-DFUR and Capecitabine chemotherapeutic effect in MC38-TP (data in submission). Such chemosensitivity related gene studies may be useful to provide effective improvement in current cancer chemotherapy. Less
期刊论文(70)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
H.Shinohara: "Expression of HER2 human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin"Journal of Surgical Research. 102. 169-177 (2002)
H.Shinohara:“HER2 人胃癌细胞的表达与重组二硫键稳定的抗 HER2 免疫毒素的抗肿瘤活性直接相关”《外科研究杂志》。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
M.Iwamoto, N.Tanigawa: "Prognostic value of tumor-infiltrating dendritic cells expressing CD38 in human breast carcinomas"Int J Cancer. 104(1). 92-97 (2003)
M.Iwamoto、N.Tanikawa:“表达 CD38 的肿瘤浸润树突状细胞在人类乳腺癌中的预后价值”Int J Cancer。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
T.Nohara: "Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients"Oncology. 60. 94-100 (2001)
T.Nohara:“细胞周期调节因子 p27 的表达与乳腺癌患者的预后和 ER 表达相关”。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
H.Kawasaki: "Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis"Cancer. 91(11). 2026-2032 (2001)
H.Kawasaki:“生存素的表达与人类结直肠肿瘤发生过程中的细胞凋亡、增殖和血管生成相关”癌症。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
T.Yamamoto: "Down-regulation of survivin expression by induction of effector cell protease receptor-1 reduces tumor growth potential with increased sensitivity to anticancer agents in human colon cancer"Eur J Cancer. 38(17). 2316-2324 (2002)
T.Yamamoto:“通过诱导效应细胞蛋白酶受体 1 下调生存素表达可降低肿瘤生长潜力,同时增加人类结肠癌对抗癌药物的敏感性”Eur J Cancer。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 28 条
In vitro chemosensitivity test to predict chemosensicivity for paclitaxel, using human gastric carcinoma tissues.
-
批准号:16209041
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$30.95万
-
财政年份:2004
-
负责人:TANIGAWA Nobuhiko
-
依托单位:
Gene therapy for augmentation chemosentivities to anticancer drugs with improvement of therapeutic index
-
批准号:10470265
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$4.1万
-
财政年份:1998
-
负责人:TANIGAWA Nobuhiko
-
依托单位:
Prediction of recurrence or metastasis of malignant tumors by assessment of their growth abilities and its clinical application
-
批准号:03454316
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$2.5万
-
财政年份:1991
-
负责人:TANIGAWA Nobuhiko
-
依托单位:
Application of a new drug screening method for clinical chemotherapy
-
批准号:63870051
-
项目类别:Grant-in-Aid for Developmental Scientific Research
-
资助金额:$3.78万
-
财政年份:1988
-
负责人:TANIGAWA Nobuhiko
-
依托单位:
Modification of Anti-cancer Drug Formula and Its Local Administration
-
批准号:63480301
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$2.3万
-
财政年份:1988
-
负责人:TANIGAWA Nobuhiko
-
依托单位: